Skip to main content
SpringerLink
Log in

Clinicopathological analysis in PTCL-NOS with CADM1 expression

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), is a heterogeneous disease with respect to clinicopathological features. Cell adhesion molecule 1 (CADM1) has been reported to be ectopically expressed in adult T cell leukaemia/lymphoma (ATLL). However, the frequency of CADM1 expression remains unknown in peripheral T cell lymphomas. In the current study, CADM1 expression was analysed in 88 PTCL-NOS patients. CADM1 was expressed in 14 of 88 (15.9%) PTCL-NOS cases, and its expression was associated with C-C chemokine receptor type 4 (CCR4) expression and nuclear atypia. CADM1-positive PTCL-NOS cases (10/74) had a significantly poorer prognosis than CADM1-negative cases (64/74) (P = 0.001). Multivariate analysis confirmed that CADM1 expression was an independent prognostic factor in PTCL-NOS. These findings suggest that CADM1 expression is a novel prognostic factor for PTCL-NOS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. WHO (2008) WHO classification of tumours of haematopoietic and lymphoid tissues (Ed 4). Lyon, France, International Agency for Research on Cancer (IARC), 306-308

  2. Kuramochi M, Fukuhara H, Nobukuni T et al (2001) TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27(4):427–430

    Article  CAS  PubMed  Google Scholar 

  3. Murakami Y (2005) Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci 96(9):543–552

    Article  CAS  PubMed  Google Scholar 

  4. Honda T, Tamura G, Waki T et al (2002) Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res 93(8):857–860

    Article  CAS  PubMed  Google Scholar 

  5. Allinen M, Peri L, Kujala S et al (2002) Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 34(4):384–389

    Article  CAS  PubMed  Google Scholar 

  6. Fukuhara H, Kuramochi M, Fukami T et al (2002) Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 93(6):605–609

    Article  CAS  PubMed  Google Scholar 

  7. Heller G, Fong KM, Girard L et al (2006) Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 25(6):959–968

    Article  CAS  PubMed  Google Scholar 

  8. Wikman H, Westphal L, Schmid F et al (2014) Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. Oncotarget 5(10):3076–3087

    Article  PubMed  PubMed Central  Google Scholar 

  9. Takahashi Y, Iwai M, Kawai T et al (2012) Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer 19(3):242–252

    Article  PubMed  Google Scholar 

  10. Kikuchi S, Iwai M, Sakurai-Yageta M et al (2012) Expression of a splicing variant of the CADM1 specific to small cell lung cancer. Cancer Sci 103(6):1051–1057

    Article  CAS  PubMed  Google Scholar 

  11. Sasaki H, Nishikata I, Shiraga T et al (2005) Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood 105(3):1204–1213

    Article  CAS  PubMed  Google Scholar 

  12. Kobayashi S, Nakano K, Watanabe E et al (2014) CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin Cancer Res 20(11):2851–2861

    Article  CAS  PubMed  Google Scholar 

  13. Nakahata S, Saito Y, Marutsuka K et al (2012) Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. Leukemia 26(6):1238–1246

    Article  CAS  PubMed  Google Scholar 

  14. Dewan MZ, Takamatsu N, Hidaka T et al (2008) Critical role for TSLC1 expression in the growth and organ infiltration of adult T-cell leukemia cells in vivo. J Virol 82(23):11958–11963

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130

    Article  PubMed  Google Scholar 

  16. Hitoshi T, Futoshi A, Masafumi K (1999) Monitoring of interobserver agreement in nuclear atypia scoring of node-negative breast carcinomas judged at individual collaborating hospitals in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Clin Oncol 29(9):413–420

    Article  Google Scholar 

  17. Kobayashi S, Watanabe E, Ishigaki T, et al (2015) Advanced HTLV-1 carriers and early-stage indolent ATLs are indistinguishable based on CADM1 positivity in flow cytometry. Cancer Sci 106(5):598-603

  18. Ansell SM, Habermann TM, Kurtin PJ et al (1997) Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 15(6):2296–2301

    Article  CAS  PubMed  Google Scholar 

  19. Gallamini A, Stelitano C, Calvi R et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474–2479

    Article  CAS  PubMed  Google Scholar 

  20. Pescarmona E, Pignoloni P, Puopolo M et al (2001) p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol 195(3):361–366

    Article  CAS  PubMed  Google Scholar 

  21. Asano N, Suzuki R, Kagami Y et al (2005) Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29(10):1284–1293

    Article  PubMed  Google Scholar 

  22. Ishida T, Inagaki H, Utsunomiya A et al (2004) CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 10(16):5494–5500

    Article  CAS  PubMed  Google Scholar 

  23. Yamada Y, Murata K, Kamihira S et al (1991) Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia. Cancer 67(10):2605–2609

    Article  CAS  PubMed  Google Scholar 

  24. Niitsu N, Nakamine H, Okamoto M (2011) Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma, not otherwise specified. Clin Cancer Res 17(9):2893–2899

    Article  CAS  PubMed  Google Scholar 

  25. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915–2923

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R et al (2014) GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 123:3007–3015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Zhang W, Wang Z, Luo Y, Zhong D, Luo Y, Zhou D (2016) GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma. Oncotarget 40(7):65284–65294

    Google Scholar 

  28. Kim H-R, Jeon B-H, Lee H-S et al (2011) IGSF4 is a novel TCR ζ-chain–interacting protein that enhances TCR-mediated signaling. J Exp Med 208(12):2545–2560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pujari R, Hunte R, Thomas R et al (2015) Human T-cell leukemia virus type 1 (HTLV-1) tax requires CADM1/TSLC1 for inactivation of the NF-kappaB inhibitor A20 and constitutive NF-kappaB signaling. PLoS Pathog 11(3):e1004721

    Article  PubMed  PubMed Central  Google Scholar 

  30. Nakagawa M, Nakagawa-Oshiro A, Karnan S et al (2009) Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res 15(1):30–38

    Article  CAS  PubMed  Google Scholar 

  31. Yoshida N, Umino A, Liu F et al (2012) Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic aberrations. Cancer Med 1(3):289–294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Mayumi Miura for outstanding technical assistance. This work was supported in part by grants from the Japan Agency for Medical Research and Development (AMED Grant number 15ck0106015h0002 for YI, MS, and KO).

Author information

Authors and Affiliations

  1. Department of Pathology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan

    Takeharu Kato, Hiroaki Miyoshi, Noriaki Yoshida, Masao Seto & Koichi Ohshima

  2. Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Takeharu Kato & Yasushi Miyazaki

  3. Division of Molecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Seiichiro Kobayashi

  4. Atomic Bomb Disease and Hibakusha Medicine Unit, Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

    Yoshitaka Imaizumi & Yasushi Miyazaki

  5. Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Kaoru Uchimaru

Authors
  1. Takeharu Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroaki Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seiichiro Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noriaki Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshitaka Imaizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masao Seto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kaoru Uchimaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasushi Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Koichi Ohshima
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TK and HM performed the research; KO designed the research; TK, HM, and KO performed the data analysis; TK, HM, NY, MS, and KO wrote the manuscript; SK, NY, YI, MS, KU, and YM supported the research; and HM and KO supervised the research. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hiroaki Miyoshi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of ethical approval

This study was approved by the Research Ethics Committee of Kurume University and was in accordance with the Declaration of Helsinki.

Electronic supplementary material

ESM 1

(PDF 84 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kato, T., Miyoshi, H., Kobayashi, S. et al. Clinicopathological analysis in PTCL-NOS with CADM1 expression. Virchows Arch 471, 659–666 (2017). https://doi.org/10.1007/s00428-017-2233-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-017-2233-9

Keywords

Search

Navigation